A degradation fragment of type X collagen is a real-time marker for bone growth velocity
Ryan F Coghlan, Jon A Oberdorf, Susan Sienko, Michael D Aiona, Bruce A Boston, Kara J Connelly, Chelsea Bahney, Jeremie LaRouche, Sarah M Almubarak, Daniel T Coleman, Irute Girkontaite, Klaus von der Mark, Gregory P Lunstrum, William A Horton, Ryan F Coghlan, Jon A Oberdorf, Susan Sienko, Michael D Aiona, Bruce A Boston, Kara J Connelly, Chelsea Bahney, Jeremie LaRouche, Sarah M Almubarak, Daniel T Coleman, Irute Girkontaite, Klaus von der Mark, Gregory P Lunstrum, William A Horton
Abstract
Despite its importance as a key parameter of child health and development, growth velocity is difficult to determine in real time because skeletal growth is slow and clinical tools to accurately detect very small increments of growth do not exist. We report discovery of a marker for skeletal growth in infants and children. The intact trimeric noncollagenous 1 (NC1) domain of type X collagen, the marker we designated as CXM for Collagen X Marker, is a degradation by-product of endochondral ossification that is released into the circulation in proportion to overall growth plate activity. This marker corresponds to the rate of linear bone growth at time of measurement. Serum concentrations of CXM plotted against age show a pattern similar to well-established height growth velocity curves and correlate with height growth velocity calculated from incremental height measurements in this study. The CXM marker is stable once collected and can be accurately assayed in serum, plasma, and dried blood spots. CXM testing may be useful for monitoring growth in the pediatric population, especially responses of infants and children with genetic and acquired growth disorders to interventions that target the underlying growth disturbances. The utility of CXM may potentially extend to managing other conditions such as fracture healing, scoliosis, arthritis, or cancer.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Figures
References
- Long F., Ornitz D. M., Development of the endochondral skeleton. Cold Spring Harb. Perspect. Biol. 5, a008334 (2013).
- Yeung Tsang K., Wa Tsang S., Chan D., Cheah K. S. E., The chondrocytic journey in endochondral bone growth and skeletal dysplasia. Birth Defects Res. C Embryo Today 102, 52–73 (2014).
- Horton W. A., Tuan R. S., Jacenko O., International workshop on the skeletal growth plate Stevenson, Washington, June 11–15, 2006. Matrix Biol. 26, 324–329. (2007).
- Kronenberg H. M., Developmental regulation of the growth plate. Nature 423, 332–336 (2003).
- de Onis M., Branca F., Childhood stunting: A global perspective. Matern. Child Nutr. 12 (Suppl. 1), 12–26 (2016).
- Baron J., Sävendahl L., De Luca F., Dauber A., Phillip M., Wit J. M., Nilsson O., Short and tall stature: A new paradigm emerges. Nat. Rev. Endocrinol. 11, 735–746 (2015).
- Melmed S., Polonsky K. S., Larsen P. R., Kronenberg H. M., Williams Textbook of Endocrinology (Elsevier, ed. 13, 2016).
- Bonafe L., Cormier-Daire V., Hall C., Lachman R., Mortier G., Mundlos S., Nishimura G., Sangiorgi L., Savarirayan R., Sillence D., Spranger J., Superti-Furga A., Warman M., Unger S., Nosology and classification of genetic skeletal disorders: 2015 revision. Am. J. Med. Genet. A 167, 2869–2892 (2015).
- Tanner J. M., Whitehouse R. H., Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child. 51, 170–179 (1976).
- Voss L. D., Bailey B. J., Cumming K., Wilkin T. J., Betts P. R., The reliability of height measurement (the Wessex Growth Study). Arch. Dis. Child. 65, 1340–1344 (1990).
- Voss L. D., Wilkin T. J, Bailey B. J., Betts P. R., The reliability of height and height velocity in the assessment of growth (the Wessex Growth Study). Arch. Dis. Child. 66, 833–837 (1991).
- Van den Broeck J., Hokken-Koelega A., Wit J., Validity of height velocity as a diagnostic criterion for idiopathic growth hormone deficiency and Turner syndrome. Horm. Res. 51, 68–73 (1999).
- Schmid T. M., Linsenmayer T. F., A short chain (pro)collagen from aged endochondral chondrocytes. Biochemical characterization . J. Biol. Chem. 258, 9504–9509 (1983).
- Schmid T. M., Linsenmayer T. F., Immunohistochemical localization of short chain cartilage collagen (type X) in avian tissues. J. Cell Biol. 100, 598–605 (1985).
- Linsenmayer T. F., Eavey R. D., Schmid T. M., Type X collagen: A hypertrophic cartilage-specific molecule. Pathol. Immunopathol. Res. 7, 14–19 (1988).
- Girkontaite I., Frischholz S., Lammi P., Wagner K., Swoboda B., Aigner T., Von der Mark K., Immunolocalization of type X collagen in normal fetal and adult osteoarthritic cartilage with monoclonal antibodies. Matrix Biol. 15, 231–238 (1996).
- Bogin O., Kvansakul M., Rom E., Singer J., Yayon A., Hohenester E., Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NC1 domain trimer. Structure 10, 165–173 (2002).
- Schmid T. M., Mayne R., Jeffrey J. J., Linsenmayer T. F., Type X collagen contains two cleavage sites for a vertebrate collagenase. J. Biol. Chem. 261, 4184–4189 (1986).
- Ochsner U. A., Green L. S., Gold L., Janjic N., Systematic selection of modified aptamer pairs for diagnostic sandwich assays. Biotechniques 56, 125–133 (2014).
- Rohloff J. C., Gelinas A. D., Jarvis T. C., Ochsner U. A., Schneider D. J., Gold L., Janjic N., Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents. Mol. Ther. Nucleic Acids 3, e201 (2014).
- Centers for Disease Control and Prevention , National Center for Health Statistics, CDC Growth Charts: United States (2000); available at .
- Tanner J. M., Davies P. S., Clinical longitudinal standards for height and height velocity for North American children. J. Pediatr. 107, 317–329 (1985).
- Einhorn T. A., Gerstenfeld L. C., Fracture healing: Mechanisms and interventions. Nat. Rev. Rheumatol. 11, 45–54 (2015).
- Lu C., Hansen E., Sapozhnikova A., Hu D., Miclau T., Marcucio R. S., Effect of age on vascularization during fracture repair . J. Orthop. Res. 26, 1384–1389 (2008).
- Taormina D. P., Shulman B. S., Karia R., Spitzer A. B., Konda S. R., Egol K. A., Older age does not affect healing time and functional outcomes after fracture nonunion surgery. Geriatr. Orthop. Surg. Rehabil. 5, 116–121 (2014).
- McDade T. W., Burhop J., Dohnal J., High-sensitivity enzyme immunoassay for C-reactive protein in dried blood spots. Clin. Chem. 50, 652–654 (2004).
- Ortega N., Behonick D. J., Werb Z., Matrix remodeling during endochondral ossification. Trends Cell Biol. 14, 86–93 (2004).
- Halberg N., Schraw T. D., Wang Z. V., Kim J.-Y., Yi J., Hamilton M. P., Luby-Phelps K., Scherer P. E., Systemic fate of the adipocyte-derived factor adiponectin. Diabetes 58, 1961–1970 (2009).
- Dupin M., Fortin T., Larue-Triolet A., Surault I., Beaulieu C., Gouel-Cheron A., Allaouchiche B., Asehnoune K., Roquilly A., Venet F., Monneret G., Lacoux X., Roitsch C. A., Pachot A., Charrier J.-P., Pons S., Impact of serum and plasma matrices on the titration of human inflammatory biomarkers using analytically validated SRM assays . J. Proteome Res. 15, 2366–2378 (2016).
- Little R. R., Rohlfing C. L., The long and winding road to optimal HbA1c measurement. Clin. Chim. Acta 418, 63–71 (2013).
- Gamble K. L., Berry R., Frank S. J., Young M. E., Circadian clock control of endocrine factors. Nat. Rev. Endocrinol. 10, 466–475 (2014).
- Lampl M., Veldhuis J. D., Johnson M. L., Saltation and stasis: A model of human growth. Science 258, 801–803 (1992).
- Heinrichs C., Munson P. J., Counts D. R., Cutler G. B. Jr., Baron J., Patterns of human growth. Science 268, 442–447 (1995).
- Kotwicki T., Chowanska J., Kinel E., Czaprowski D., Tomaszewski M., Janusz P., Optimal management of idiopathic scoliosis in adolescence. Adolesc. Health Med. Ther. 4, 59–73 (2013).
- Goldring M. B., Berenbaum F., Emerging targets in osteoarthritis therapy. Curr. Opin. Pharmacol. 22, 51–63 (2015).
- He Y., Siebuhr A. S., Brandt-Hansen N. U., Wang J., Su D., Zheng Q., Simonsen O., Petersen K. K., Arendt-Nielsen L., Eskehave T., Hoeck H. C., Karsdal M. A., Bay-Jensen A. C., Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. BMC Musculoskelet. Disord. 15, 309 (2014).
- Solé X., Crous-Bou M., Cordero D., Olivares D., Guinó E., Sanz-Pamplona R., Rodriguez-Moranta F., Sanjuan X., de Oca J., Salazar R., Moreno V., Discovery and validation of new potential biomarkers for early detection of colon cancer. PLOS ONE 9, e106748 (2014).
- Chapman K. B., Prendes M. J., Sternberg H., Kidd J. L., Funk W. D., Wagner J., West M. D., COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol. 8, 1031–1040 (2012).
- Wagner K., Pöschl E., Turnay J., Baik J.-M., Pihlajaniemi T., Frischholz S., von der Mark K., Coexpression of α and β subunits of prolyl 4-hydroxylase stabilizes the triple helix of recombinant human type X collagen. Biochem. J. 352 (Pt. 3), 907–911 (2000).
- Eng J. K., Searle B. C., Clauser K. R., Tabb D. L., A face in the crowd: Recognizing peptides through database search. Mol. Cell Proteomics 10, R111.009522 (2011).
- Ochsner U. A., Katilius E., Janjic N., Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers. Diagn. Microbiol. Infect. Dis. 76, 278–285 (2013).
- Armbruster D. A., Pry T., Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 29, S49–S52 (2008).
Source: PubMed